• What is Pinkeye?
• Economic cost
• Predisposing factors
• Clinical signs
• Treatment
• Prevention

• Mode of action
• Dose rate & administration
• Vaccination schedule
• Efficacy & safety
• Cross-reactivity
• Why vaccinate?
• OH&S
• Product lnformation

Cross-Reactivity

There have been a number of strains of M. bovis identified as being important in causing pinkeye in Australian cattle. Coopers Piliguard Pinkeye-1 Trivalent Vaccine is a one dose trivalent vaccine against three strains of M. bovis. These strains are referred to as Moraxella bovis FLA64, SAH38 and EPP63.

In 2003, twenty five veterinary practices located throughout the intensive cattle producing regions of Australia participated in a study whereby ocular swabs were collected from cattle with pinkeye. From these swabs, 70 M. bovis samples were attained, representing pinkeye outbreaks on 44 properties. In 34 (77.27%) of these outbreaks, the M. bovis isolated cross-reacted with one of the strains in the Piliguard vaccine.


Serologic cross-reactivity of M. bovis isolates (from each outbreak by state of origin) with the strains contained in Piliguard⁴.








Serologic cross-reactivity of M. bovis isolates (from each outbreak by type of animal production) with the strains contained in Piliguard⁴.










The study concluded that a pinkeye vaccine containing these strains of M. bovis
would provide a management tool to minimise infection and decrease the
detrimental effects in the majority of Australian pinkeye outbreaks in both beef
and dairy cattle.


Coopers® PILIGUARD® Pinkeye-1 Trivalent Vaccine is the first commercially
available pinkeye vaccine in Australia, and provides an aid in the prevention
of pinkeye caused by strains of Moraxella bovis expressing pili similar to those
used in the vaccine.